Journal Home
Search for

Volume 52, Issue 6, Pages 1174-1179 (December 2008)


View previous. 20 of 37 View next.

Rejection Versus Posttransplantation Lymphoproliferative Disorder in a Renal Transplant Recipient

Megan L. Troxell, MD, PhD1Corresponding Author Informationemail address, Jennifer B. Dunlap, MD1, Anuja Mittalhenkle, MD2, Mona Ishag, MD3, Guang Fan, MD, PhD1, James Z. Huang, MD1, Ken Gatter, JD, MD1, Dan M. Byrd, MD4, Devon Webster, MD4, Donald C. Houghton, MD1

Received 28 January 2008; accepted 22 April 2008. published online 15 August 2008.

Article Outline

Case Report

Clinical History

Kidney Biopsy

Clinical Follow-up

Discussion

Acknowledgment

References

Copyright

Posttransplantation lymphoproliferative disorder (PTLD) is a complication of both solid-organ and hematopoietic cell transplantation. The risk of PTLD increases with the intensity of immunosuppression and/or mass of transplanted lymphoid cells. Thus, kidney transplant recipients have a relatively low risk of 1.0% to 1.5%, and one-third to one-half of these involve the renal allograft itself.1, 2, 3, 4, 5, 6 Epstein-Barr virus (EBV)-negative recipients have 25- to 70-fold greater risk of PTLD compared with seropositive recipients.1, 2, 3 Other PTLD risk factors include concomitant cytomegalovirus or other viral infection and recent anti–T-cell therapy, such as OKT3 or thymoglobulin.2, 3, 6

EBV, a DNA virus of the Herpes virus family, is central to the pathogenesis of PTLD. EBV infects cells, mainly B lymphocytes, through the CD21 receptor and causes B-cell proliferation.1, 7 EBV establishes latency after infection. Cytotoxic T cells generally keep EBV-driven proliferation in check; however, this function is impaired in immunosuppressed patients.

We report a case of PTLD in an adult after a primary EBV infection and discuss the histopathologic differential diagnosis of the renal biopsy, treatment, and outcome.

Case Report 

return to Article Outline

Clinical History 

A 56-year-old man presented in acute renal failure with a serum creatinine level of 8.1 mg/dL (618 μmol/L). He had received a living unrelated donor renal transplant 4.5 years before, with bilateral native nephrectomies, for autosomal dominant polycystic kidney disease. The graft was a 6-antigen mismatch, and he received basiliximab (anti–interleukin 2 receptor α) induction. His posttransplantation course was uncomplicated, except for subclinical acute cellular tubulointerstitial rejection (CCTT/Banff type I) on the 3-month surveillance biopsy specimen, which resolved with pulse steroid treatment. Maintenance immunosuppression consisted of triple therapy with tacrolimus (FK506), 3 mg twice daily; azathioprine, 200 mg/d; and prednisone, 10 mg/d. Serum creatinine level was slightly increased (2.2 mg/dL [168 μmol/L]) 1 month before presentation (baseline, 1.7 mg/dL [130 μmol/L]).

The patient had an extensive travel history and presented immediately on return from a trip to Asia for elective cosmetic surgery. While abroad, he experienced fever, chills, night sweats, malaise, and right suprascapular pain and received injections of unknown medications, presumably an antibiotic and a nonsteroidal anti-inflammatory. At presentation, laboratory data included negative or normal C3, C4, antinuclear antibody, rheumatoid factor, anti–glomerular basement membrane, hepatitis B and C, and polyoma BK viral study results, with a low-titer antineutrophil cytoplasmic antibody (1:20). Renal ultrasound showed a 15-cm allograft kidney. A concurrent chest computed tomographic scan showed numerous 2- to 5-mm pulmonary nodules, along with several poorly defined opacities in the left lower lobe, each 1 to 2 cm in diameter, and right lower lobe consolidation. There was mediastinal adenopathy and an 18-cm spleen. A renal allograft biopsy was performed on hospital day 1, followed 3 days later by a computed tomography–guided needle biopsy of the lung.

Kidney Biopsy 

The renal allograft biopsy specimen was remarkable for a diffuse, dense, mixed interstitial inflammatory cell infiltrate composed of lymphocytes, numerous eosinophils, fewer neutrophils, and very rare plasma cells. Lymphocytic tubulitis was readily identified. There were clustered vaguely spindle-shaped histiocytes suggestive of poorly formed granulomas and patchy zones of necrosis, some with accompanying hemorrhage. Fibrinoid change in adjacent small arteries also was seen; 1 was occluded by swollen endothelial cells and foamy debris. Venulitis was present, but there was no other evidence of arterial endothelialitis. Rare cells with large nuclei and irregular nuclear contours were seen in the background, along with rare interstitial mitotic figures (Fig 1A to C). Six sampled glomeruli were unremarkable.


View full-size image.

Figure 1. Histopathologic findings in kidney biopsy specimen. (A) Mixed inflammatory cell infiltrate with numerous eosinophils, eosinophilic tubulitis (arrows), and tubular injury. (B) Interstitial inflammatory infiltrate including large atypical cells. (Inset) Cells with (left) irregular nuclear contour and (right) macronucleolus. (C) Vascular findings at edge of necrosis: (∗) vessel with fibrinoid change, (arrowheads outline) artery with lumen occluded by flocculent material with lymphocytes, and (arrow) interstitial mitotic figure in histiocyte-rich area. (D) Immunohistochemical staining of serial sections shows the infiltrate is composed of a majority of (left) small CD3-positive T cells and (right, matched field) a minority of small CD20 positive B-cells. (E) Immunohistochemical staining of serial sections shows (left) CD30 stains clusters of cells, including large cells, whereas (right) PAX5 highlights few B cells, including (matched field) a rare cell with large nucleus. (F) Epstein-Barr virus (EBV) in situ hybridization highlights numerous infiltrating cells; positive signal is blue with red counterstain (original magnifications ×400).


The histopathologic differential diagnosis centered on a drug/hypersensitivity reaction, infection, rejection, PTLD, or Hodgkin lymphoma. Histochemical stains were negative for bacterial, mycobacterial, and fungal organisms; immunostains for BK polyoma virus and C4d were also negative. A panel of hematolymphoid markers showed that the infiltrate was composed of numerous CD3-positive T cells, with a minority of CD20- and/or PAX5-positive small and rare large B cells (Fig 1D and E). CD30 highlighted increased numbers of medium-sized immunoblasts, some in clusters (Fig 1E), but Reed-Sternberg cells or variants were not apparent on special studies, including CD15 staining. In situ hybridization for EBV encoded RNA (EBER-ISH) was strikingly positive, especially in CD30- and PAX5-labeled foci (Fig 1F). Gene rearrangement studies were attempted, but were unsuccessful. Based on the rare atypical lymphoid cells, zones of ischemic necrosis, and immunohistochemical profile, most notably EBV positivity, a diagnosis of PTLD (infectious mononucleosis–like) was favored.

A needle core biopsy specimen of the lung showed different pathological features: extensive necrosis and sheets of lymphoid cells of variable size and nuclear morphological characteristics, including numerous large cells with atypical nuclei (Fig 2A). In addition, an angiocentric pattern was noted, with lymphocytes infiltrating the full thickness of the wall of the arteries (not shown). By immunohistochemical staining, CD20 labeled the majority of lymphocytes (B cells; Fig 2B), including medium to large cells and necrotic cells. CD30 stained a subset of large B cells, and CD3 showed admixed T cells. Again, EBER-ISH was positive. Molecular studies showed a clonal B-cell population. Histological, immunohistochemical, and molecular findings were diagnostic of monomorphic PTLD, diffuse large B-cell lymphoma, with a lymphomatoid granulomatosis-like pattern.8, 9


View full-size image.

Figure 2. Histopathologic findings in lung biopsy and allograft nephrectomy specimens. (A) Lung with dense monomorphic lymphoid infiltrate effaces pulmonary architecture. (B) CD20 staining shows B-cell phenotype. (C) Allograft nephrectomy with (lower left) glomerular ischemia, (upper right) prominent oxalate crystals, tubular atrophy, interstitial fibrosis, and non-atypical lymphocytes. (D) Chronic allograft arteriopathy with scant lymphoid infiltrate (original magnification: [A-C] ×400; [D] ×200).


Clinical Follow-up 

On transfer, the patient had sepsis caused by Klebsiella species and colitis caused by Clostridium difficile, and hematologic studies showed neutrophilia (90% on differential), anemia (hematocrit, 28.7%), and thrombocytopenia (platelets, 78.0 K/μL); atypical lymphocytes were not seen. He had underlying cardiac ischemia and ejection fraction of 18% on echocardiogram and was tolerating hemodialysis poorly. Initially, therapy consisted of a decrease in immunosuppression followed by single-agent rituximab given his comorbidities (375 mg/m2/wk for 4 weeks,10, 11 with prednisone, 10 mg/d, and tacrolimus, 0.5 mg twice weekly [target serum levels, 3 to 5 ng/mL]). In addition, the patient developed an acute abdomen and underwent sigmoid resection for ruptured diverticulitis. The patient recovered from these acute events and was discharged home on dialysis therapy 1 month after presentation. Maintenance rituximab was administered every 3 months.

EBV serological test samples drawn during hospitalization were consistent with late convalescence of a primary infection (Table 1). Review of transplantation data showed the patient was EBV- and cytomegalovirus-naïve at that time; the donor was also cytomegalovirus negative, with unknown EBV status.

Table 1.

Epstein-Barr Virus Test Results

Index Value at Renal Transplantation (2002)Index Value During Hospital Admission (2007)
Viral capsid antigen IgG0.5412.15
Viral capsid antigen IgM0.000.15
Nuclear antigen, IgG0.360.95
Early (D) antigen, IgG0.121.87

Note: Interpretation: index values 0 to 0.90 indicate negative; 0.91 to 0.99, equivocal; and greater than 1.00, positive.

Abbreviation: IgG, immunoglobulin G; IgM, immunoglobulin M.

Computed tomographic scan at discharge showed resolution of the small lung nodules and decrease in size of the opacities. Three months later, the lung nodules had resolved completely; however, allograft kidney function did not recover, and a graft nephrectomy was performed 5 months after the initial presentation. The patient remains in remission 11 months after the initial presentation.

Histopathologic evaluation of the allograft nephrectomy showed diffuse interstitial fibrosis and tubular atrophy with numerous calcium oxalate crystals. There was no acute rejection, but there were focal loose collections of small non-atypical lymphocytes (Fig 2C and D). Lymphocytes were EBER-ISH negative (not shown), and there was no evidence of PTLD. Several arteries contained luminal or intimal cholesterol clefts. Arteries showed marked fibrous intimal hyperplasia with concentric intimal smooth muscle, consistent with chronic allograft arteriopathy/chronic vascular rejection, but no endothelialitis. Glomeruli showed ischemic features and mesangial sclerosis, with 12% global glomerulosclerosis.

Discussion 

return to Article Outline

This case illustrates an unusual histopathologic presentation of PTLD, with divergent pathological findings in lung and kidney, and shows the broad spectrum of histological features associated with PTLD. Histopathologic features of the initial renal biopsy specimen, together with the clinical history, prompted a clinicopathologic differential diagnosis of a hypersensitivity/drug reaction, infection, rejection, and/or lymphoproliferative disorder. However, the presence of atypical lymphoid cells, along with special study results, supported the diagnosis of PTLD.

Pathological features of PTLD are highly varied, thought to be partly related to the stage of B-cell development affected. The current World Health Organization classification system outlines 4 pathological categories of PTLD7, 12: (1) early PTLD lesions include infectious mononucleosis–like, atypical lymphoid hyperplasia, or plasmacytic hyperplasia; (2) polymorphic PTLDs are destructive mass-like lesions with a nonmonotonous population of predominantly B cells; (3) monomorphic PTLDs show histological, immunophenotypic, and genetic features of lymphoma and are subclassified further according to World Health Organization classification of B- or T-cell lymphoma; only 10% to 15% are of T-cell derivation; and (4) Hodgkin or Hodgkin-like PTLD. Up to 20% of cases may be negative for EBV.7, 12

PTLD in kidney typically presents as nodular expansile aggregates of lymphoid cells with architectural effacement.4, 6, 7, 12, 13, 14 However, early PTLD may show considerable overlap with rejection, and differentiation may be difficult in allograft biopsy specimens. In comparative studies of renal allograft specimens, Randhawa et al4, 13 described tubulitis, arteritis, and venulitis in both PTLD and rejection. However, expansile interstitial mononuclear infiltrates, predominance of B cells, nuclear atypia, and serpinginous necrosis were relatively specific for PTLD.

Strongly positive EBV study results in allograft kidney biopsy tissue provide evidence in support of PTLD. In the nephrectomy series of Randhawa et al,13 none of 9 rejection specimens were EBV positive, whereas all 9 PTLD cases were positive. However, rare EBV-positive lymphocytes have been described in allograft kidneys in non-PTLD circumstances (<1% of lymphocytes, rarely up to 10%).4, 15, 16 Although the present patient lacked typical mass lesions, EBV study results supported the diagnosis of PTLD. Furthermore, coexistence of PTLD and rejection may occur and can be diagnosed by endothelialitis composed of non-atypical EBV-negative lymphocytes; in the setting of B-cell PTLD, T-cell endothelialitis supports rejection.5, 13

This case also illustrates the discordant histological characteristics of PTLD lesions in different sites as the lung biopsy specimen showed diffuse large B-cell lymphoma. Unfortunately, the paucity of tissue did not allow direct comparison of the clonality of kidney and lung PTLD. Discordant PTLDs have been reported rarely in individual case studies (Table 2). Biopsy of additional sites of disease, if any, has been recommended when a first biopsy specimen shows an early or polyclonal PTLD lesion.7

Table 2.

Discordant PTLD Literature Review

ReferenceOrgan TransplantPTLD SitePTLD Features
Harris et al7HeartColonMultiple sites, polymorphic and monomorphic, each different clonality
Frankel et al17KidneyScalpB cell
BloodClonal T cell
Euvrard et al18KidneySkinT cell
Lymph nodesT and B cell
Nelson et al19LiverBone marrow, spleenClonal T-cell (Hodgkin disease–like) predominant
Bone marrow, liverClonal B-cell predominant
Collins et al20LiverLymph nodesNot clonal, monomorphic
BowelClonal B cell, monomorphic
Koh et al21LiverLiverEarly, mononucleosis-like
Liver, lymph nodes, pancreasB cell, monomorphic
Chuhjo et al22Bone marrowBloodClonal B and clonal T cell
Yin et al23KidneyLymph nodesClonal B cell, polymorphous
Liver, bone marrowClonal T cell, dyssynchronous
Heyny-von Haussen et al24Kidney, pancreasKidneyClonal B cell, donor origin, polymorphic
LiverClonal B cell, host origin, polymorphic
Central nervous systemClonal B cell, host origin, polymorphic
Present studyKidneyKidneyEarly, mononucleosis-like; clonality unknown
LungClonal B cell, monomorphic (diffuse large B-cell lymphoma)

Abbreviation: PTLD, posttransplantation lymphoproliferative disorder.

First-line therapy for patients with PTLD generally involves reduction in immunosuppression to restore endogenous T-cell function. This paradigm is most efficacious in patients with early polyclonal lesions.1, 12 However, patients with monomorphic PTLD generally require treatment equivalent to that for primary lymphoma. Small prospective series have investigated monotherapy with the anti-CD20 agent rituximab as second-line therapy for PTLD and showed a complete response rate of 42% to 57%, with better response in EBV-positive patients.1, 10, 11, 25, 26 The patient reported here had a complete response to rituximab monotherapy. Patients with relapse and those without complete response to anti-CD20 monotherapy may still respond to traditional cytotoxic chemotherapy.10, 11, 26

In summary, this case illustrates how closely PTLD may mimic other entities on renal allograft biopsy; thus, PTLD is an important differential diagnostic consideration for any specimen with an inflammatory cell infiltrate, along with rejection, infection, hypersensitivity, and other causes of interstitial nephritis. A high index of suspicion, along with EBV studies, are invaluable in reaching the correct diagnosis. In this case, despite diffuse large B-cell lymphoma in the lung, complete remission was obtained with rituximab monotherapy.

Acknowledgements 

return to Article Outline

We thank Dr Anthony Bakke, Oregon Health & Science University, for helpful discussion of EBV serological studies and acknowledge the expert technical assistance of Histology and Immunohistochemistry laboratory staff at Oregon Health and Science University and Kaiser Permanente.

Support: None.

Financial Disclosure: None.

References 

return to Article Outline

1. 1Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology (Carlton). 2006;11:355–366. MEDLINE | CrossRef

2. 2Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med. 2007;131:1209–1218.

3. 3Shroff R, Rees L. The post-transplant lymphoproliferative disorder—A literature review. Pediatr Nephrol. 2004;19:369–377. CrossRef

4. 4Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ, Nalesnik M. Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol. 1996;20:563–571. MEDLINE | CrossRef

5. 5Trpkov K, Marcussen N, Rayner D, Lam G, Solez K. Kidney allograft with a lymphocytic infiltrate: Acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities?. Am J Kidney Dis. 1997;30:449–454. Abstract | Full-Text PDF (3949 KB) | CrossRef

6. 6Weiss M, Liapis H, Tomaszewski JE, Arend LJ. Pyelonephritis and other infections, reflux nephropathy, hydronephrosis, and nephrolithiasis. In:  Jennette JC,  Olson JL,  Schwartz MM,  Silva FG editor. Heptinstall's Pathology of the Kidney. Philadelphia, PA: Lippincott Williams & Wilkins; 2007;p. 1010–1034.

7. 7Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14:8–14. MEDLINE

8. 8Saxena A, Dyker KM, Angel S, Moshynska O, Dharampaul S, Cockroft DW. Posttransplant diffuse large B-cell lymphoma of “lymphomatoid granulomatosis” type. Virchows Arch. 2002;441:622–628. MEDLINE | CrossRef

9. 9Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849.

10. 10Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial. Cancer. 2005;104:1661–1667.

11. 11Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901–2906. MEDLINE | CrossRef

12. 12Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplantation lymphoproliferative disorder. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001;p. 264–269.

13. 13Randhawa P, Demetris AJ, Pietrzak B, Nalesnik M. Histopathology of renal posttransplant lymphoproliferation: Comparison with rejection using the Banff schema. Am J Kidney Dis. 1996;28:578–584. Abstract | Full-Text PDF (799 KB) | CrossRef

14. 14Vogler C, Wang Y, Brink DS, Wood E, Belsha C, Walker PD. Renal pathology in the pediatric transplant patient. Adv Anat Pathol. 2007;14:202–216. MEDLINE | CrossRef

15. 15Arias LF, Hernandez S, Prats D, et al. Epstein-Barr virus latency in kidney specimens from transplant recipients. Nephrol Dial Transplant. 2003;18:2638–2643. MEDLINE | CrossRef

16. 16Cosio FG, Nuovo M, Delgado L, et al. EBV kidney allograft infection: Possible relationship with a peri-graft localization of PTLD. Am J Transplant. 2004;4:116–123. MEDLINE | CrossRef

17. 17Frankel AH, Thompson M, Vulliamy T, et al. A T cell clone in association with an Epstein-Barr virus-related B cell lymphoma. Transplantation. 1991;52:1108–1109. MEDLINE | CrossRef

18. 18Euvrard S, Noble CP, Kanitakis J, et al. Brief report: Successive occurrence of T-cell and B-cell lymphomas after renal transplantation in a patient with multiple cutaneous squamous-cell carcinomas. N Engl J Med. 1992;327:1924–1926. MEDLINE

19. 19Nelson BP, Locker J, Nalesnik MA, Fung JJ, Swerdlow SH. Clonal and morphological variation in a posttransplant lymphoproliferative disorder: Evolution from clonal T-cell to clonal B-cell predominance. Hum Pathol. 1998;29:416–421. Abstract | Full-Text PDF (4749 KB) | CrossRef

20. 20Collins MH, Montone KT, Leahey AM, et al. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics. 2001;107:E89.

21. 21Koh BY, Rosenthal P, Medeiros LJ, et al. Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation. Arch Pathol Lab Med. 2001;125:337–343. MEDLINE

22. 22Chuhjo T, Yachie A, Kanegane H, Kimura H, Shiobara S, Nakao S. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation. Am J Hematol. 2003;72:255–258. MEDLINE | CrossRef

23. 23Yin CC, Medeiros LJ, Abruzzo LV, Jones D, Farhood AI, Thomazy VA. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient. Am J Clin Pathol. 2005;123:222–228. MEDLINE | CrossRef

24. 24Heyny-von Haussen R, Klingel K, Riegel W, Kandolf R, Mall G. Posttransplant lymphoproliferative disorder in a kidney-pancreas transplanted recipient: Simultaneous development of clonal lymphoid B-cell proliferation of host and donor origin. Am J Surg Pathol. 2006;30:900–905. MEDLINE | CrossRef

25. 25Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis. 2004;39:1016–1023. CrossRef

26. 26Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol. 2007;86:599–607. MEDLINE | CrossRef

1 Department of Pathology, Division of Nephrology and Hypertension, Oregon Health & Science University, Portland, OR

2 Department of Medicine, Division of Nephrology and Hypertension, Oregon Health & Science University, Portland, OR

3 Department of Pathology, Kaiser Permanente, Oregon Health & Science University, Portland, OR

4 Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR

Corresponding Author InformationAddress correspondence to Megan L. Troxell, MD, PhD, Department of Pathology, L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239

 Originally published online as doi:10.1053/j.ajkd.2008.04.033 on August 13, 2008.

PII: S0272-6386(08)01004-4

doi:10.1053/j.ajkd.2008.04.033


View previous. 20 of 37 View next.